Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RESOLVE

Financiado

Cerrado

tPA Nanoconstructs for Treating Acute Ischemic Stroke a Technical and Commercia...

tPA Nanoconstructs for Treating Acute Ischemic Stroke a Technical and Commercial Analysis Acute ischemic strokes result from the occlusion of cerebral vessels by blood clots causing neurological complications, brain damage and death. Based on WHO reports, stroke affects 17M people per year worldwide, with 6M deaths and... ver más

31/12/2021

IIT

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-12-31

ERC-2018-PoC: ERC Proof of Concept Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

IIT

150.00K€ | Lider

Kyb Steering Spain, SA

1.05M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2014-56336-R NANONEUROPROTECCION TERMO-MOLECULAR VECTORIZADA EN LA ISQUEM... 218K€ Cerrado

OP2DRAIN To deliver the first medical treatment dedicated to patients... 11M€ Cerrado

IMPACT IMproved Plasminogen Activator based on Cerium oxide nanopar... 212K€ Cerrado

NAD NANOPARTICLES FOR THERAPY AND DIAGNOSIS OF ALZHEIMER DISEASE 14M€ Cerrado

SAF2016-80427-R POLIMEROS TERAPEUTICOS DISEÑADOS PARA CRUZAR LA BARRERA HEMA... 206K€ Cerrado

PCI2022-134986-2 THERAGNOSTIC TARGETING OF EXTRACELLULAR MATRIX METALLOPROTEI... 175K€ Cerrado

Duración del proyecto: 33 meses Fecha Inicio: 2019-03-14
Fecha Fin: 2021-12-31

Líder del proyecto

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Acute ischemic strokes result from the occlusion of cerebral vessels by blood clots causing neurological complications, brain damage and death. Based on WHO reports, stroke affects 17M people per year worldwide, with 6M deaths and 5M survivors suffering long-lasting disabilities. Recent statistics estimate an EU direct healthcare cost for stroke of €20B and indirect costs, due to disabilities and lost productivity, of €25B. The two current treatments – thrombolysis and thrombectomy – come with limitations and considerable side effects. Thrombolysis can be safely administered only to a small cohort of patients (about 5%) whereas thrombectomy induces disabilities in 50% of the cases. Moved by the societal, economical, and emotional burden associated with stroke, this proposal aims at developing and validating more effective and less toxic therapies via the combination of the clinically approved molecule tPA and rationally-designed, discoidal polymeric nanoconstructs (DPNs). As compared to tPA, the proposed thrombolytic nano-agents (tPA-DPNs) are expected to provide faster blood clot dissolution; safer administration profile; longer blood circulation and stability. On the technical side, tPA-DPNs will be re-designed to improve their biodegradation and excretion profiles; validated in FDA-recognized stroke models for neurotoxicity and therapeutic efficacy. On the commercial side, a patent portfolio covering the fabrication and utilization of tPA-DPNs will be secured, together with thorough market and business analyses. This will facilitate the interaction with pharmaceutical companies that are investing in the fast growing markets of high-tech drug delivery systems and stroke diagnostics and therapies. tPA-DPNs are expected to alleviate the economic burden on healthcare systems, increase the total sale of thrombolytic agents, revolutionize the medical protocols for stroke management, and diminish the societal and emotional impact of stroke.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores